title: Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter.
abstract: Leukocytapheresis therapy has been used to try to treat such intractable diseases as autoimmune and neurologic diseases, achieving good results. However, a number of problems have been identified in leukocyte removal by thoracic duct drainage or continuous centrifugal separation; namely the high risk, expensive cost, and complicated operation. Asahi Medical Co. has developed an innovative solution for such conventional problems. Its new leukocyte removal filter (Cellsorba) is capable of removing white blood cells by perfusion of whole blood by means of simple extracorporeal circulation. Leukocytapheresis therapy using the Cellsorba column is being confirmed as extremely effective for many inflammatory diseases, as well as in autoimmune and neurologic diseases. This paper outlines information about the Cellsorba column and introduces several reports on therapeutic results.
authors.forename: J
authors.initials: J
authors.lastname: Suemitsu
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: N
authors.initials: N
authors.lastname: Yamawaki
authors.forename: Y
authors.initials: Y
authors.lastname: Yamashita
mesh_terms: D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D005112:Extracorporeal Circulation / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D005434:Flow Cytometry; D006801:Humans; D007937:Leukapheresis / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D011091:Polyesters; D016896:Treatment Outcome
chemical_list: D011091:Polyesters; D002097:C-Reactive Protein